Daniela Bota, MD of UC Irvine Health gives an overview of the final results of the TAVAREC trial, which studied…
Daniela Bota, MD of UC Irvine Health discusses a phase II clinical trial called the CEVOREM study, which focused on…
Daniela Bota, MD of UC Irvine Health gives an overview of the AURA3 trial and the use of osimertinib in…
Daniela Bota, MD of UC Irvine Health gives her take on Senator John McCain’s recent diagnosis of glioblastoma. She further…
Viola Zhu, MD, PhD of UC Irvine Health discusses the CTONG 1104 trial and the use of gefitinib for adjuvant…
Viola Zhu, MD, PhD of UC Irvine Health discusses the AvaALL trial and the use of bevacizumab beyond progression in…
Viola Zhu, MD, PhD of UC Irvine Health gives an overview of the ARCHER 1050 trial in EGFR+ non-small cell…
Viola Zhu, MD, PhD of UC Irvine Health discusses the ALEX trial and the use of alectinib and crizotinib in…
Rita Mehta, MD of UC Irvine Health discusses the take-home message of PALOMA-1 and the impact on clinical practice at…
Rita Mehta, MD of UC Irvine Health gives an overview of the PALOMA-1 trial and the use of palbociclib and…
Rita Mehta, MD of UC Irvine Health gives an overview of the OlympiAD study, which focuses on the use of…
Rita Mehta, MD of UC Irvine Health discusses the MONARCH 2 trial and the use of abemaciclib and fulvestrant in…
Rita Mehta, MD of UC Irvine Health gives an overview of the APHINITY trial and the use of pertuzumab as…
Farshid Dayyani, MD, PhD of UC Irvine Health discusses sidedness in colorectal cancer tumors at the 2017 MOASC Spotlight on…
Farshid Dayyani, MD, PhD of UC Irvine Health gives an overview of the IDEA trial at the 2017 MOASC Spotlight…
Farshid Dayyani, MD, PhD of UC Irvine Health discusses the BRAF trial and explains how to overcome resistance to anti-EGFR…
Farshid Dayyani, MD, PhD of UC Irvine Health discusses the Immunotherapy Trials, the Keynote trial and the Checkmate trial, at…
Farshid Dayyani, MD, PhD of UC Irvine Health gives an overview of the FLOT trial, a practice-changing clinical trial in…
Sarmen Sarkissian, MD of UC Irvine Health discusses the highlights in prostate cancer research, specifically a phase III clinical trial…
Sarmen Sarkissian, MD of UC Irvine Health discusses the highlights in kidney cancer research specifically a phase II study on…
As part of a recent MPN Town Meeting in partnership with Robert H. Lurie Comprehensive Cancer Center in Chicago, Drs.…
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Tanja Cufer discusses the treatment of elderly…
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Paul Baas discusses the latest treatment options…
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Nicholas Girard discusses the treatment of carcinoids,…
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Egbert F. Smit discusses new treatment options…
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Luis Paz-Ares discusses treatment options in the…
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Sanjay Popat discusses mutation-independent approaches to the…
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Fernando López-RÃos arguest that liquid biopsy will…
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Thomas Newsom-Davis argues that liquid biopsy will…
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Luis Paz-Ares discusses HER-2, BRAF, KRAS, and…
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Céline Mascaux discusses treatment strategies in both…
With the recent news that Sen. John McCain was diagnosed with glioblastoma, Ashley Sumrall, MD, division chief of neuro-oncology at…
Surgeon Anne Peled, MD and patient Sue Yeres — herself a breast cancer activist — tell the story of Sue’s…
Dr. David Edmonson describes how the BioZorb implant helps improve cosmetic results for breast cancer patients — while also aiding…
Trisha Marsolini, RN, OCN, BMTCN and Angela Rodriguez, MSN, RN, CNS-BC, AFN-BC, OCN, Associate Director of Clinical Operations Infusion/CTU/Phase 1…
Kathleen Shannon Dorcy, PhD, RN, Director of Clinical Nursing Research of Seattle Cancer Care Alliance discusses Ethical Considerations of Precision…
Naomi Heinecke, LPN and Terri Cunningham, MSN, RN, AOCN of Seattle Cancer Care Alliance discuss Creating an Accurate Home Medication…
Arlyce Coumar, BSN, RN, OCN, BMTCN of Seattle Cancer Care Alliance discusses A Model for Global Engagement of Oncology Nurses…
Michelle Mitchell, BSN, RN, OCN, Sharon Rockwell, BSN, RN, OCN, CRNI, Alex Dorcy, BSN, RN, OCN, and Annette English, BSN,…
Nicole Falkin, BSN, RN, OCN and Anne Nagengast, BSN, RN, BMTCN of Seattle Cancer Care Alliance discuss Managing Cytokine Release…
Karen Anderson, MN, RN, AOCNS, BMTCN, CRNI and Anne Reese, BSN, RN, OCN of Seattle Cancer Care Alliance discuss Nursing…
Expanding beyond the checkpoints: New vaccines and other immunologic strategies for NSCLC Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung…
Unique toxicities of immunotherapy Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.
In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Vassiliki Papadimitrakopoulou argues in favor of the use…
In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Naiyer Rizvi argues in favor of single drug…
In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Andrew R. Haas discusses the biological basis of…
In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Joshua Bauml discusses whether there has been progress…
In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Evan W. Alley discusses the targeting of HER2,…
In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Ranee Mehra discusses the therapeutic implications of EML4/ALK,…
In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Pallavi Kumar discusses strategies for how to conduct…
In this Velocity Vlog activity, Dr. Howard L. Kaufman of the Rutgers Cancer Institute, provides a brief overview of the…
In this Ask the Expert segment, Dr. Srdan Verstovsek from The University of Texas MD Anderson Cancer Center responds to…
In this Ask the Expert segment, a Patient Power community member wants to know if and why a bone marrow…
Jack West, MD of Swedish Cancer Institute explains how anti-PD-L1 and PD-1 therapies are being incorporated into lung cancer treatment…
Jack West, MD of Swedish Cancer Institute discusses the use of IDO inhibitors for the treatment of lung cancer patients…
Jack West, MD of Swedish Cancer Institute discusses the use of durvalumab for patients with stage III non-small cell lung…
Jack West, MD of Swedish Cancer Institute explains the relevance to test for PD-L1 in lung cancer at the 2017…
Jack West, MD of Swedish Cancer Institute discusses the combination of immunotherapies for future clinical research at the 2017 Annual…
Jack West, MD of Swedish Cancer Institute explains how anti-PD-L1 and PD-1 therapies are being combined with chemotherapy and targeted…
Nicholas J. Vogelzang, MD of Comprehensive Cancer Centers of Nevada discusses the results of the LATITUDE study and its impact…
Nicholas J. Vogelzang, MD of Comprehensive Cancer Centers of Nevada explains how he chooses the right prostate cancer patient for…
Nicholas J. Vogelzang, MD of Comprehensive Cancer Centers of Nevada explains whether AR-V7 testing is ready for prime time at…
Nicholas J. Vogelzang, MD of Comprehensive Cancer Centers of Nevada discusses the data from the CHAARTED, STAMPEDE, and LATITUDE studies…
Nicholas J. Vogelzang, MD of Comprehensive Cancer Centers of Nevada discusses cost implications when abiraterone becomes standard care for prostate…
Debu Tripathy, MD of MD Anderson Cancer Center explains how immunotherapies are being studied and possibly integrated into the treatment…
Debu Tripathy, MD of MD Anderson Cancer Center gives an overview of the MONALEESA-2 study at the 2017 Annual Meeting…
Debu Tripathy, MD of MD Anderson Cancer Center gives an overview of the MONARCH-2 trial and explains its impact on…
Debu Tripathy, MD of MD Anderson Cancer Center discusses the impact of the APHINITY trial on treating patients with breast…
Anurag Singh, MD, shares new research indicating that non-small cell lung cancer (NSCLC) patients may benefit from a single dose…
Stereotactic body radiation therapy (SBRT) combined with surgery can be used to treat metastatic kidney cancer, according to Roswell Park…
George R. Simon, MD, FACP, FCCP of MD Anderson Cancer Center gives an overview of the Checkmate 032 and CTONG…
George R. Simon, MD, FACP, FCCP of MD Anderson Cancer Center gives an overview of the most promising data on…
David S. Siegel, MD, PhD of John Theurer Cancer Center discusses the use of pomalidomide for multiple myeloma patients progressing…
David S. Siegel, MD, PhD of John Theurer Cancer Center discusses the use of CAR T-cell therapy in treating multiple…
David S. Siegel, MD, PhD of John Theurer Cancer Center discusses the combination of pembrolizumab and lenalidomide for treating patients…
Jeff Sharman, MD of Willamette Valley Cancer Center discusses whether or not CAR T-cell therapy is promising for the treatment…
Jeff Sharman, MD of Willamette Valley Cancer Center gives an overview of his presentation, which focused on the GENUINE trial…
Jeff Sharman, MD of Willamette Valley Cancer Center discusses the emerging trends for management of chronic lymphocytic leukemia at the…
Leonard Saltz, MD of Memorial Sloan Kettering Cancer Center discusses how and when he beings to speak with his patients…
Leonard Saltz, MD of Memorial Sloan Kettering Cancer Center gives an overview of the most intriguing and most promising clinical…
Leonard Saltz, MD of Memorial Sloan Kettering Cancer Center discusses how to control rising drug prices without impacting the value…
Leonard Saltz, MD of Memorial Sloan Kettering Cancer Center explains the optimal duration of adjuvant chemotherapy in colon cancer at…
Leonard Saltz, MD of Memorial Sloan Kettering Cancer Center discusses the interventions to alleviate financial toxicity at the 2017 Annual…
Philip Philip, MD of Karmanos Cancer Institute discusses duration of therapy and whether or not shorter treatments will have the…
Philip Philip, MD of Karmanos Cancer Institute discusses the use of lenvatinib in patients with unresectable hepatocellular carcinoma (HCC) at…
Philip Philip, MD of Karmanos Cancer Institute discusses the possible benefits of the use of immunotherapy in gastrointestinal diseases at…
Philip Philip, MD of Karmanos Cancer Institute gives his take on the use of capecitabine in biliary cancers at the…
Philip Philip, MD of Karmanos Cancer Institute discusses the impact of PEGPH20 on care of patients with metastatic pancreatic cancer…
Daniel Petrylak, MD of Yale School of Medicine discusses which tests patients with urothelial carcinoma should receive as part of…
Daniel Petrylak, MD of Yale School of Medicine discusses what’s next for patient with bladder cancer after checkpoint inhibition therapy…
Daniel Petrylak, MD of Yale School of Medicine discusses the role of checkpoint inhibition therapy in urothelial carcinoma cancer at…
Daniel Petrylak, MD of Yale School of Medicine discusses whether or not prostate cancer guidelines should be updated based on…
Andrew L. Pecora, MD, FACP, CPE of John Theurer Cancer Center discusses the collaboration between COTA and IBM Watson Health…
Andrew L. Pecora, MD, FACP, CPE of John Theurer Cancer Center discusses the implications of healthcare and reimbursement reform on…
Andrew L. Pecora, MD, FACP, CPE of John Theurer Cancer Center discusses what tools do oncologists need as they move…
Andrew L. Pecora, MD, FACP, CPE of John Theurer Cancer Center discusses how healthcare reform and the move from volume…
Debra Patt, MD, MPH, MBA, VP of Texas Oncology explains what utilization management is and why it is important in…
Debra Patt, MD, MPH, MBA, VP of Texas Oncology discusses implementing an informatics-enabled oncology practice at the 2017 Annual Meeting…
Debra Patt, MD, MPH, MBA, VP of Texas Oncology discusses the future of the 340B program, which requires pharmaceutical companies…
Debra Patt, MD, MPH, MBA, VP of Texas Oncology discusses the importance of patrolling drug costs and reimbursements for Texas…
Debra Patt, MD, MPH, MBA, VP of Texas Oncology discusses why she has not been incorporating liquid biopsies into patient…
Randall Oyer, MD of Ann B. Barshinger Cancer Institute and Lancaster General Health discusses the collaboration between the Association of…
Randall Oyer, MD of Ann B. Barshinger Cancer Institute and Lancaster General Health discusses the challenges and solutions Lancaster General…
Randall Oyer, MD of Ann B. Barshinger Cancer Institute and Lancaster General Health discusses the major themes coming out of…
Randall Oyer, MD of Ann B. Barshinger Cancer Institute and Lancaster General Health discusses how Oncology Care Model (OCM) is…
Andrew Norden, MD of IBM Watson Health gives an overview of the data demonstrating clinical utility for Watson for Oncology…
Andrew Norden, MD of IBM Watson Health discusses future developments for IBM Watson at the 2017 Annual Meeting Annual Meeting…
Andrew Norden, MD of IBM Watson Health discusses IBM Watson’s library of tumor types and what it takes to add…
Andrew Norden, MD of IBM Watson Health explains how the Watson for Clinical Trial Matching tool matches patients to clinical…
Jeffrey Meyehardt, MD of Harvard Medical School discusses the use of vemurafenib in BRAF+ mutated metastatic colorectal cancer at the…
Jeffrey Meyehardt, MD of Harvard Medical School explains whether or not selective internal radiation therapy (SIRT) is effective in treating…
Jeffrey Meyehardt, MD of Harvard Medical School discusses the optimal duration of therapy for patients with stage III colon cancer…
Jeffrey Meyehardt, MD of Harvard Medical School discusses how immunotherapy is being studied and implemented in the treatment of gastric…
Christopher J. Logothetis, MD of MD Anderson Cancer Center discusses how he identifies and chooses the right patients for abiraterone…
Christopher J. Logothetis, MD of MD Anderson Cancer Center discusses whether or not AR-V7 is ready for prime time at…
Christopher J. Logothetis, MD of MD Anderson Cancer Center compares the three trials, CHAARTED, STAMPEDE, and LATITUDE, and discusses how…
Christopher J. Logothetis, MD of MD Anderson Cancer Center discusses the impact of cost with the introduction of abiraterone as…
Christopher J. Logothetis, MD of MD Anderson Cancer Center discusses why the LATITUDE study will be practice changing for the…
Kathryn Kolibaba, MD of US Oncology Research discusses the general takeaways from the oral sessions on lymphoma presented at the…
Kathryn Kolibaba, MD of US Oncology Research discusses the MAGNIFY study and its impact on high-risk indolent NHL patients at…
Kathryn Kolibaba, MD of US Oncology Research gives an overview of the results from the BRIGHT study and its impact…
Edward Kim, MD of Levine Cancer Institute discusses the use of immunotherapy combinations for future treatment of patients with lung…
Edward Kim, MD of Levine Cancer Institute discusses the use of gefitinib versus standard chemotherapy for patients with stage II-IIIA…
Edward Kim, MD of Levine Cancer Institute explains how anti-PD-L1 and PD-1 therapies are being combined with chemotherapy and targeted…
Edward Kim, MD of Levine Cancer Institute discusses the biggest updates in lung cancer research, which include the breakthrough of…
Mohammad Jahanzeb, MD, FACP of Sylvester Comprehensive Cancer Center discusses the APHINITY trial and its impact on clinical practice and…
Mohammad Jahanzeb, MD, FACP of Sylvester Comprehensive Cancer Center discusses the differences and similarities between CDK 4/6 inhibitors at the…
Mohammad Jahanzeb, MD, FACP of Sylvester Comprehensive Cancer Center discusses how immunotherapy is being studied and integrated into the treatment…
Mohammad Jahanzeb, MD, FACP of Sylvester Comprehensive Cancer Center discusses the impact of the MONARCH-2 trial on treating patients with…
Sundar Jagannath, MD of Icahn School of Medicine at Mount Sinai gives an overview of the most promising studies on…
Sundar Jagannath, MD of Icahn School of Medicine at Mount Sinai discusses what physicians should be aware of when sequencing…
Sundar Jagannath, MD of Icahn School of Medicine at Mount Sinai explains how personalized medicine will impact the treatment of…
Howard Hochster, MD of Yale Cancer Center discusses the impact of immunotherapy for the treatment of gastric and GE junction…
Howard Hochster, MD of Yale Cancer Center discusses whether or not stage III colon cancer patients should be treated with…
Howard Hochster, MD of Yale Cancer Center discusses new peri-operative treatment regimens for resectable gastric and GE junction cancers at…
Howard Hochster, MD of Yale Cancer Center gives an overview of treatments for BRAF-mutated positive colorectal cancer patients at the…
Patricia Goldsmith, CEO of CancerCare discusses the new data on patient-focused initiatives presented at the 2017 Annual Meeting Annual Meeting…
Patricia Goldsmith, CEO of CancerCare discusses the tools that cancer patients should have as they progress on their journey. This…
Patricia Goldsmith, CEO of CancerCare discusses the financial programs that are provided by CancerCare for cancer patients to help with…
Richard M. Goldberg, MD, FAnnual Meeting of West Virginia University Cancer Institute discusses the use of pembrolizumab in tumor-agnostic MSI-high…
Richard M. Goldberg, MD, FAnnual Meeting of West Virginia University Cancer Institute gives an overview of the promising data presented…
Richard M. Goldberg, MD, FAnnual Meeting of West Virginia University Cancer Institute discusses the optimal duration of therapy for a…
Richard M. Goldberg, MD, FAnnual Meeting of West Virginia University Cancer Institute explains how he defines a high-risk from a…
Robert Figlin, MD of Samuel Oschin Comprehensive Cancer Institute explains the use of checkpoint inhibitors is changing the treatment standards…
Robert Figlin, MD of Samuel Oschin Comprehensive Cancer Institute discusses his thoughts on sequencing when treating patients with metastatic renal…
Robert Figlin, MD of Samuel Oschin Comprehensive Cancer Institute explains how he stratifies metastatic RCC patients to choose the most…
Robert Figlin, MD of Samuel Oschin Comprehensive Cancer Institute gives an overview of the promising data on renal cell carcinoma…
Robert Figlin, MD of Samuel Oschin Comprehensive Cancer Institute discusses the future impact of new therapies for renal cell carcinoma…
Neelima Denduluri, MD of Virginia Cancer Specialists gives an overview of the phase III study, the APHINITY trial, and its…
Neelima Denduluri, MD of Virginia Cancer Specialists gives an overview of the new approaches in treatment of breast cancer at…
Neelima Denduluri, MD of Virginia Cancer Specialists discusses how CDK 4/6 inhibitors are changing the treatment of breast cancer at…
Neelima Denduluri, MD of Virginia Cancer Specialists explains how the results of the MONARCH-2 study will change future treatment of…
Nancy Dawson, MD of Lombardi Cancer Center at Georgetown University Hospital discusses the difference in side effects between abiraterone and…
Nancy Dawson, MD of Lombardi Cancer Center at Georgetown University Hospital discusses how physicians should treat hormone-sensitive advanced prostate cancer…
Nancy Dawson, MD of Lombardi Cancer Center at Georgetown University Hospital gives an overview of the STAMPEDE study, which focuses…
Nancy Dawson, MD of Lombardi Cancer Center at Georgetown University Hospital discusses her thoughts on the LATITUDE study for prostate…
Nevena Damnjanov, MD of Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania discusses how she reliably identifies subgroups for…
Nevena Damnjanov, MD of Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania gives an overview of what she learned…
Nevena Damnjanov, MD of Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania explains how new agents being studied will…
Nevena Damnjanov, MD of Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania discusses the use of lenvatinib in the…
Barbara Ann Burtness, MD of Yale Cancer Center gives an overview of the LUX Head and Neck 2 trial, which…
Barbara Ann Burtness, MD of Yale Cancer Center explains the use of bevacizumab plus chemotherapy for the treatment of patients…
Barbara Ann Burtness, MD of Yale Cancer Center explains whether or not patients with head and neck cancers should be…
Barbara Ann Burtness, MD of Yale Cancer Center discusses how immunotherapies are being integrated into head and neck cancer treatments…
Phil Bonomi, MD of Rush University Medical Center discusses how immunotherapies are being integrated into the treatment of small cell…
Phil Bonomi, MD of Rush University Medical Center discusses whether or not MET inhibitors are effective in the treatment of…
Noa Biran, MD of John Theurer Cancer Center discusses which novel agents to use in the treatment of multiple myeloma.…
Noa Biran, MD of John Theurer Cancer Center discusses personalized medicine for the treatment of multiple myeloma patients at the…
Noa Biran, MD of John Theurer Cancer Center explains how immunotherapies are being integrated into treatment of multiple myeloma at…
Noa Biran, MD of John Theurer Cancer Center discusses induction therapy for treatment of multiple myeloma patients at the 2017…
J. Thaddeus Beck, MD, FACP of Highlands Oncology Group explains whether or not the Watson for Clinical Trials Matching tool…
J. Thaddeus Beck, MD, FACP of Highlands Oncology Group discusses how the Watson for Clinical Trials Matching tool work at…
J. Thaddeus Beck, MD, FACP of Highlands Oncology Group discusses the design of the Watson for Clinical Trials Matching tool…
Lyudmila Bazhenova, MD of UC San Diego Health explains whether or not ALK inhibitors can be sequenced in clinical practice…
Lyudmila Bazhenova, MD of UC San Diego Health discusses what physicians should expect when treating ALK positive lung cancer patients…
Lyudmila Bazhenova, MD of UC San Diego Health explains how to choose one ALK inhibitor over the others at the…
Lyudmila Bazhenova, MD of UC San Diego Health discusses the reliability of the ALK biomarker and whether or not physicians…
Aref Al-Kali, MD of Mayo Clinic discusses some of the challenges in treating elderly acute myeloid leukemia patients at the…
Aref Al-Kali, MD of Mayo Clinic discusses the use of the Leukostat test in clinical practice, which was approved with…
Aref Al-Kali, MD of Mayo Clinic discusses the approval of midostaurin for FLT3+ AML patients. This was recorded at the…
Aref Al-Kali, MD of Mayo Clinic discusses the important data presented on FLT3 mutant AML at the 2017 Annual Meeting…
An educational overview of facts in Childhood Cancer | Pediatric Oncology (an educational tool designed to be shared by healthcare…
Overview of facts in breast cancer (an educational tool designed to be shared by healthcare professionals with patients and caregivers)
H. Jack West, MD of Swedish Cancer Institute gives an overview of the use of gefinitib compared to standard chemotherapy…
H. Jack West, MD of Swedish Cancer Institute discusses the updated results of the KEYNOTE-021 study for patients with advanced…
H. Jack West, MD of Swedish Cancer Institute discusses an abstract that focused on the efficacy and safety of a…
H. Jack West, MD of Swedish Cancer Institute discusses the results of the ARCHER 1050 trial for non-small cell lung…
H. Jack West, MD of Swedish Cancer Institute discusses the results of the ALEX trial for ALK+ non-small cell lung…
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology discusses the take home of the POLLUX and CASTOR…
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology argues that the take-home message for the follow-up on…
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology discusses the take-home message of the LATITUDE study at…
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology gives an overview of the POLLUX/CASTOR studies, which looked…
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology discusses the LATITUDE trial, a phase III trial on…
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology gives an overview a four year follow-up study on…
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology summarizes common questions that are asked regarding the updates…
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology explains a common question that’s usually asked regarding the…
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology explains which combination improved survival for patients with prostate…
Katja Weisel, MD of Janssen Oncology gives an overview of her abstract, which focuses on two randomized phase III trials…
Katja Weisel, MD of Janssen Oncology explains further the next steps for the POLLUX and CASTOR trials which include extending…
Katja Weisel, MD of Janssen Oncology discusses the impact of the POLLUX and CASTOR trial on clinical practice, which are…
Katja Weisel, MD of Janssen Oncology summarizes a poster presentation that focused on the anti-CD38 antibody in refractory myeloma patients…
Liza Villaruz, MD of University of Pittsburgh Medical Center discusses the next steps for the clinical trial at the 2017…
Liza Villaruz, MD of University of Pittsburgh Medical Center discusses the impact of atezolizumab on clinical practice and future clinical…
Liza Villaruz, MD of University of Pittsburgh Medical Center gives an overview of the practice-changing data on lung cancer at…
Liza Villaruz, MD of University of Pittsburgh Medical Center gives an overview of her presentation, which focuses on the use…
Jalaja Potluri, MD of AbbVie Inc. discusses what’s next for her study and her hopes for the drug to become…
Jalaja Potluri, MD of AbbVie Inc. discusses common questions colleagues ask regarding her study at the 2017 ASCO Annual Meeting…
Jalaja Potluri, MD of AbbVie Inc. gives an overview of her abstract, a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of…
Jalaja Potluri, MD of AbbVie Inc. discusses the treatment trends for 2017 in acute myeloid leukemia at the 2017 ASCO…
Nathan Pennell, MD, PhD of Cleveland Clinic discusses what’s next for his study on maintenance pembrolizumab for patients with small…
Nathan Pennell, MD, PhD of Cleveland Clinic gives an overview of his abstract, which focused on the use of maintenance…
Nathan Pennell, MD, PhD of Cleveland Clinic discusses common questions that colleagues ask him regarding pembrolizumab, which is if there…
Nathan Pennell, MD, PhD of Cleveland Clinic summarizes promising presentations on targeted treatments in patients with non-small cell lung cancer…
Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. gives an overview of Advaxis’ Lm Technology, which alters Listeria monocytogenes…
Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. explains what axalimogene filolisbac is and the use of it in…
Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. summarizes the pipeline of Lm Technology at the 2017 ASCO Annual…
Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. explains how Lm Technology works in the system and what are…
Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. summarizes the practice-changing studies on immuno-oncology coming out of ASCO 2017.…
Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. discusses the NEO program which is a collaboration between Amgen and…
Andrew Norden, MD of IBM Watson Health discusses the future of Watson for Oncology in clinical practice at the 2017…
Andrew Norden, MD of IBM Watson Health summarizes the use of Watson technology in the field of oncology at the…
Andrew Norden, MD of IBM Watson Health discusses questions and concerns colleagues have regarding Watson for Oncology, which include whether…
Aly-Khan Lalani, MD of Dana-Farber Cancer Institute discusses the next steps for his study, which include combining c-met targeted therapies…
Aly-Khan Lalani, MD of Dana-Farber Cancer Institute gives an overview of his presentation, Differential expression of c-Met between primary and…
Aly-Khan Lalani, MD of Dana-Farber Cancer Institute summarizes the common questions colleagues ask him concerning his study on c-Met expression…
Aly-Khan Lalani, MD of Dana-Farber Cancer Institute gives an overview of practice-changing data coming out of ASCO on metastatic hormone-sensitive…
Mark M. Awad, MD, PhD of Dana-Farber Cancer Institute gives an overview of his abstract, Impact of MET inhibitors on…
Mark M. Awad, MD, PhD of Dana-Farber Cancer Institute discusses common questions colleagues ask him regarding his abstract at the…
Mark M. Awad, MD, PhD of Dana-Farber Cancer Institute discusses the impact of his study on clinical practice and future…
Mark M. Awad, MD, PhD of Dana-Farber Cancer Institute summarizes the next steps for METdel14 mutations and MET inhibitors for…
J. Thaddeus Beck, MD, FACP of Highlands Oncology Group gives an overview of his presentation, which focused on the use…
J. Thaddeus Beck, MD, FACP of Highlands Oncology Group discusses common questions colleagues ask him regarding the IBM Watson platform…
J. Thaddeus Beck, MD, FACP of Highlands Oncology Group discusses the impact of IBM Watson on clinical practice and future…
Shailender Bhatia, MD of Seattle Cancer Care Alliance discusses his first presentation, which focused on the results of the KEYNOTE-029…
Shailender Bhatia, MD of Seattle Cancer Care Alliance discusses his second presentation, which focused on the use of nivolumab plus…
Shailender Bhatia, MD of Seattle Cancer Care Alliance discusses what the next steps are for these two clinical trials and…
Brian Rini, MD of Cleveland Clinic gives an overview of the poster presentations on kidney cancer at the 2017 ASCO…
Brian Rini, MD of Cleveland Clinic gives an overview of his poster presentation which focuses on the use of sunitinib…
Brian Rini, MD of Cleveland Clinic discusses the treatment trends for kidney cancer in the next couple of years which…
Sharad A. Ghamande, MD of Medical College of Georgia discusses the take-home message of the AIM2CERV trial at the 2017…
Sharad A. Ghamande, MD of Medical College of Georgia discusses how he communicates and encourages his patients to participate in…
Sharad A. Ghamande, MD of Medical College of Georgia gives an overview of poster presentations he found the most interesting…
Sharad A. Ghamande, MD of Medical College of Georgia discusses the unmet need for cervical cancer and the promising data…
Aditya Bardia, MD, MPH of Harvard Medical School and Massachusetts General Hospital Cancer Center gives an overview of the treatment…
Aditya Bardia, MD, MPH of Harvard Medical School and Massachusetts General Hospital Cancer Center discusses the next step for RAD1901…
Aditya Bardia, MD, MPH of Harvard Medical School and Massachusetts General Hospital Cancer Center gives an overview of his presentation,…
Aditya Bardia, MD, MPH of Harvard Medical School and Massachusetts General Hospital Cancer Center discusses common questions he’s asked regarding…
Adi Diab, MD of MD Anderson Cancer Center discusses the treatment trends for 2017 in oncology, which include combining immunotherapies…
Adi Diab, MD of MD Anderson Cancer Center gives an overview of the promising data on intratumoral therapy that was…
Adi Diab, MD of MD Anderson Cancer Center discusses the impact of cytokine therapy and NKTR-214 on clinical practice and…